QPPV.COM KNOWLEDGE ASSESSMENT

Blinatumomab: CD19–CD3 T-cell engagement, acute lymphoblastic leukaemia, and product pharmacovigilance

Test your understanding of the concepts covered by Blinatumomab: CD19–CD3 T-cell engagement, acute lymphoblastic leukaemia, and product pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which data combination would be most useful when evaluating a suspected blinatumomab-related inflammatory event?

Only the patient's treatment indication Cycle and day, tumour burden, dose step, premedication, vital signs, organ involvement and competing infection evidence Only the final outcome after hospital discharge Only the product batch number without clinical chronology

Question 2 of 10 Which combination most appropriately supports prevention and early detection of TLS in a patient with high tumour burden?

Avoid hydration and monitor only blood pressure Use risk-based cytoreduction, hydration, urate-lowering therapy and close monitoring of electrolytes, uric acid and renal function Administer intrathecal chemotherapy alone and omit biochemical monitoring Monitor immunoglobulins only because TLS is an antibody-mediated event

Question 3 of 10 A pump malfunction causes an uncertain interruption and possible underdose during home infusion. Which information is most important in the medication-error report?

Only whether the patient reported fever Only the name of the prescribing physician Prescribed dose, concentration, programmed rate, timing, residual volume, alarms and estimated actual exposure Only the patient's diagnosis and age

Question 4 of 10 Why does blinatumomab not replace intrathecal CNS-directed therapy in ALL?

Blinatumomab directly destroys cerebrospinal fluid proteins Systemic CD19–CD3 engagement is not a substitute for validated treatment of CNS sanctuary disease Intrathecal therapy is used only to prevent B-cell aplasia Blinatumomab is a BCR::ABL1 inhibitor and therefore cannot enter the CNS

Question 5 of 10 Why is the distinction between an Fc-free bispecific and a long-lived full-IgG bispecific important for pharmacovigilance?

Molecular format affects persistence, exposure pattern, interruption consequences and potentially the timing and management of toxicity Molecular format has no relevance once both products bind CD3 Full-IgG bispecifics cannot cause CRS or neurological events Fc-free molecules always require permanent treatment discontinuation after any adverse event

Question 6 of 10 A patient develops relapse with loss of CD19 expression after prior blinatumomab. Which conclusion is most appropriate?

CD19 loss can provide a route of immune escape and may make further CD19-directed therapy less suitable The relapse proves that blinatumomab directly activated BCR::ABL1 CD19 loss demonstrates that the original diagnosis was necessarily incorrect CD19 loss means that all B-lineage antigens, including CD22 and CD20, are absent

Question 7 of 10 Which finding would most strongly support tumour lysis syndrome rather than isolated CRS in a patient who develops fever after treatment initiation?

A transient headache with normal renal function Hyperkalaemia, hyperphosphataemia, hyperuricaemia and acute kidney injury A positive blood culture with a catheter-site focus A new handwriting abnormality without metabolic changes

Question 8 of 10 Which feature most directly explains why very low concentrations of blinatumomab may produce substantial biological effects?

The drug is converted into a high-dose chemotherapy metabolite Each activated T cell can proliferate and kill multiple targets through serial killing The drug accumulates permanently in bone marrow CD19-positive cells amplify blinatumomab through enzymatic replication

Question 9 of 10 Which molecular feature most directly explains why blinatumomab requires continuous intravenous infusion?

Its Fc region causes rapid clearance through complement activation Its Fc-free, small fragment-based structure is associated with a short elimination half-life Its binding to CD19 is irreversible and requires continuous receptor replacement Its cytotoxic payload must be continuously replenished in the bloodstream

Question 10 of 10 Why can flushing the infusion line at the end of a blinatumomab bag create a clinically important medication error?

Flushing chemically inactivates the drug and causes treatment failure The line contains residual drug that may be delivered rapidly as an unintended bolus Flushing prevents any subsequent use of the dedicated lumen The line flush causes CD19 to be expressed on T cells

QPPV.com

Blinatumomab: CD19–CD3 T-cell engagement, acute lymphoblastic leukaemia, and product pharmacovigilance

Cookie Settings